{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:54:40Z","timestamp":1791960880998,"version":"4.3.4"},"reference-count":52,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma, with generally favorable outcomes but a variable clinical course. Recent studies have elucidated the consistent and reproducible frequency of early disease progression in FL, occurring in \u223c20% of patients. Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk of death. Currently, there is no established method of identifying patients at risk for early disease progression at the time of their FL diagnosis. However, numerous studies worldwide are investigating clinical, pathologic, and radiographic biomarkers to help predict POD24, thereby improving subsequent outcomes and adapting therapy based on individual risk. There is also a paucity of standardized treatments for patients with POD24, but investigations are ongoing testing novel targeted therapies and autologous stem cell transplantation strategies. This review provides an overview of early-relapsing FL and our approach to patient management based on recent available data.<\/jats:p>","DOI":"10.1182\/blood-2018-08-822148","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T19:26:08Z","timestamp":1548876368000},"page":"1540-1547","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["How I treat early-relapsing follicular lymphoma"],"prefix":"10.1182","volume":"133","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021109271558600_B1","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes [published online ahead of print 12 September 2016]","author":"Teras","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2020021109271558600_B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2020021109271558600_B3","first-page":"1089","article-title":"Expression of the bcl-2 gene product in follicular lymphoma","volume":"140","author":"Gaulard","year":"1992","journal-title":"Am J Pathol"},{"issue":"6","key":"2020021109271558600_B4","first-page":"539","article-title":"CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles","volume":"122","author":"Almasri","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2020021109271558600_B5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020021109271558600_B6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"25","key":"2020021109271558600_B7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","article-title":"Expression in non-Hodgkin\u2019s lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation","volume":"318","author":"Ngan","year":"1988","journal-title":"N Engl J Med"},{"issue":"6","key":"2020021109271558600_B8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020021109271558600_B9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021109271558600_B10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2020021109271558600_B11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"9759","key":"2020021109271558600_B12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"suppl 1","key":"2020021109271558600_B13","article-title":"Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study [abstract]","volume":"130","author":"Launonen","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020021109271558600_B14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021109271558600_B15","article-title":"Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials [abstract]","volume":"130","author":"Casulo","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2020021109271558600_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2953.2953","article-title":"Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB studies 50402, 50701 and 50803 (Alliance) [abstract]","volume":"128","author":"Lansigan","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020021109271558600_B17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2020021109271558600_B18","article-title":"Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma [abstract]","volume":"132","author":"Freeman","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021109271558600_B19","article-title":"Outcomes of follicular lymphoma patients treated with frontline bendamustine and rituximab: impact of histologic grade and early progression on overall survival [abstract]","volume":"132","author":"Winter","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020021109271558600_B20","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"8","key":"2020021109271558600_B21","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2020021109271558600_B22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"30","key":"2020021109271558600_B23","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020021109271558600_B24","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"27","key":"2020021109271558600_B25","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020021109271558600_B26","article-title":"Surveillance imaging during first-remission in follicular lymphoma does not impact overall survival [abstract]","volume":"130","author":"Goldman","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2020021109271558600_B27","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020021109271558600_B28","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020021109271558600_B29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020021109271558600_B30","doi-asserted-by":"crossref","first-page":"djw255","DOI":"10.1093\/jnci\/djw255","article-title":"Recommendations for clinical trial development in follicular lymphoma","volume":"109","author":"Maddocks","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 2","key":"2020021109271558600_B31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hon.2437_13","article-title":"Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12 year follow-up of the EBMT lymphoma working party LYM1 trial [abstract]","volume":"35","author":"Pettengell","year":"2017","journal-title":"Hematol Oncol"},{"issue":"14","key":"2020021109271558600_B32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021109271558600_B33","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2020021109271558600_B34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.bbmt.2017.05.021","article-title":"Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure","volume":"23","author":"Jimenez-Ubieto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020021109271558600_B35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hon.2553","article-title":"Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment","volume":"36","author":"Jim\u00e9nez-Ubieto","year":"2018","journal-title":"Hematol Oncol"},{"issue":"6","key":"2020021109271558600_B36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109271558600_B37","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020021109271558600_B38","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"issue":"31","key":"2020021109271558600_B39","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2020021109271558600_B40","article-title":"Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL) [abstract]","volume":"35","author":"Andorsky","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2020021109271558600_B41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hon.2437_36","article-title":"A phase II LYSA study of obinutuzumab combined with lenalidomide for relapsed or refractory follicular B cell lymphoma [abstract]","volume":"35","author":"Morschhauser","year":"2017","journal-title":"Hematol Oncol"},{"issue":"11","key":"2020021109271558600_B42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"35","key":"2020021109271558600_B43","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2020021109271558600_B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2437_57","article-title":"DYNAMO: a phase 2 study demonstrating the clinical activity og duvelisib in patients with double refractory indolent non hodgkin lymphoma [abstract]","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2020021109271558600_B45","article-title":"Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma [abstract]","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2020021109271558600_B46","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"suppl 15","key":"2020021109271558600_B47","article-title":"Activity of TGR-1202, a novel once-daily PI3K\u03b4 inhibitor, in patients with relapsed or refractory hematologic malignancies [abstract]","volume":"32","author":"Burris","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 14","key":"2020021109271558600_B48","article-title":"Differential regulation of human T-cells by TGR-1202, a novel PI3K\u03b4 inhibitor [abstract]","volume":"76","author":"Maharaj","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"2020021109271558600_B49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020021109271558600_B50","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2020021109271558600_B51","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021109271558600_B52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/14\/1540\/1552917\/blood822148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/14\/1540\/1552917\/blood822148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T10:10:26Z","timestamp":1581415826000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/14\/1540\/260517\/How-I-treat-earlyrelapsing-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":52,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,4,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-08-822148","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]}}}